Sánchez-López Araceli, Centurión David, Vázquez Erika, Arulmani Udayasankar, Saxena Pramod R, Villalón Carlos M
Departamento de Farmacobiología, CINVESTAV-IPN, Czda. de los Tenorios 235, Col. Granjas-Coapa, Deleg. Tlalpan, C.P. 14330, México D.F., México.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):220-7. doi: 10.1007/s00210-003-0842-0. Epub 2003 Dec 12.
Serotonin (5-hydroxytryptamine; 5-HT) is capable of inhibiting the tachycardic responses elicited by sympathetic stimulation, but not by exogenous noradrenaline, in pithed rats pre-treated with desipramine. More recently, it has been shown that this cardiac sympatho-inhibitory response to 5-HT, mediated by prejunctional 5-HT1 receptors as well as putative 5-ht5A/5B receptors, is mimicked dose-dependently by the agonists CP 93,129 (r5-HT1B), sumatriptan (5-HT1B/1D) and PNU-142633 (5-HT1D). This study analysed further the pharmacological profile of the above 5-HT1 receptors. Continuous i.v. infusions of CP 93,129, sumatriptan or PNU-142633 (30 micro g kg(-1)min(-1) each) failed to modify the tachycardic responses to exogenous noradrenaline but inhibited those elicited by preganglionic (C7-T1) stimulation of the cardiac sympathetic outflow. These sympatho-inhibitory responses were unaltered after i.v. administration of physiological saline (1 ml kg(-1)) or the 5-HT1A receptor antagonist WAY 100635 (10 micro g kg(-1)). In contrast, the antagonist GR 127935 (5-HT1B/1D; 100 micro g kg(-1), i.v.) abolished the responses to CP 93,129, sumatriptan and PNU-142633, whilst SB224289 (5-HT1B; 300 micro g kg(-1), i.v.) abolished the responses to CP 93,129 without affecting those to sumatriptan and PNU-142633. Interestingly, BRL15572 (5-HT1D; 300 micro g kg(-1), i.v.) abolished the responses to PNU-142633 and attenuated those to sumatriptan, but not those to CP 93,129. WAY 100635, GR 127935, SB224289 and BRL15572, given alone at the above doses, failed to modify the sympathetically induced tachycardic responses. The 5-HT1 receptors producing cardiac sympatho-inhibition in pithed rats thus display the pharmacological profile of the 5-HT1B and 5-HT1D receptor subtypes.
在预先用去甲丙咪嗪处理的脊髓横断大鼠中,血清素(5-羟色胺;5-HT)能够抑制交感神经刺激引发的心动过速反应,但不能抑制外源性去甲肾上腺素引发的反应。最近的研究表明,这种对5-HT的心脏交感神经抑制反应,由突触前5-HT1受体以及假定的5-ht5A/5B受体介导,可被激动剂CP 93,129(r5-HT1B)、舒马曲坦(5-HT1B/1D)和PNU-142633(5-HT1D)剂量依赖性地模拟。本研究进一步分析了上述5-HT1受体的药理学特征。持续静脉输注CP 93,129、舒马曲坦或PNU-142633(各30μg kg(-1)min(-1))未能改变对外源性去甲肾上腺素的心动过速反应,但抑制了由心脏交感神经传出纤维的节前(C7-T1)刺激引发的反应。静脉注射生理盐水(1 ml kg(-1))或5-HT1A受体拮抗剂WAY 100635(10μg kg(-1))后,这些交感神经抑制反应未改变。相比之下,拮抗剂GR 127935(5-HT1B/1D;100μg kg(-1),静脉注射)消除了对CP 93,129、舒马曲坦和PNU-142633的反应,而SB224289(5-HT1B;300μg kg(-1),静脉注射)消除了对CP 93,129的反应,而不影响对舒马曲坦和PNU-142633的反应。有趣的是,BRL15572(5-HT1D;300μg kg(-1),静脉注射)消除了对PNU-142633的反应,并减弱了对舒马曲坦的反应,但不影响对CP 93,129的反应。以上述剂量单独给予WAY 100635、GR 127935、SB224289和BRL15572,未能改变交感神经诱导的心动过速反应。因此,在脊髓横断大鼠中产生心脏交感神经抑制的5-HT1受体表现出5-HT1B和5-HT1D受体亚型的药理学特征。